Violation Tracker Individual Record
Date:August 18, 2015
Offense Group:healthcare-related offenses
Primary Offense:off-label or unapproved promotion of medical products
Amgen agreed to pay $71 million to settle multistate litigation alleging that it unlawfully promoted its biologic medications Aranesp and Enbrel for unapproved uses.
Level of Government:state
Action Type:agency action
Agency:Multistate Attorneys General Case
Civil or Criminal Case:civil
HQ Country of Parent:USA
HQ State of Parent:California
Ownership Structure of Parent:publicly traded
Major Industry of Parent:pharmaceuticals
Specific Industry of Parent:pharmaceuticals
Source Notes:If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.